Interim report - SciBase

Interim report - SciBase

PR Newswire

STOCKHOLM, Nov. 13, 2018

STOCKHOLM, Nov. 13, 2018 /PRNewswire/ --

January 1September 30, 2018

The third quarter in figures

The first 9-months in figures

Important events during the quarter

Important events after the end of the period






 

Oct 1 2017 -



 

July1 - Sep 30

Jan 1 - Sep 30

Sep 30 2018

Jan 1 - Dec 31

 

THE GROUP

 

2018

 

2017

 

2018

 

2017

 

Rolling-12

2017

 

Net sales, SEK ths

 

1 359

 

1 172

 

4 869

 

4 973

6 755

 

6 859

 

Gross margin, %

 

52,6%

 

56,8%

 

51,9%

 

36,8%

 

46,2%

 

35,4%

 

Equity/Asset ratio, %

 

89,2%

 

86,9%

 

89,2%

 

86,9%

 

88,2%

 

90,5%

 

Net indebtness, multiple

 

0,12

 

0,15

 

0,12

 

0,15

 

0,13

 

0,11

 

Cash equivalents, SEK ths

 

77 551

 

50 948

 

77 551

 

50 948

 

77 551

 

110 015

 

Cashflow from operating activities, SEK ths

 

-7 692

 

-9 796

 

-27 492

 

-32 821

 

-38 850

 

-44 180

 

Earnings per share (before and after dilution), SEK

 

-0,77

 

-1,06

 

-1,97

 

-3,88

 

-3,40

 

-5,00

 

Shareholder's equity per share, SEK

 

4,97

 

7,31

 

4,97

 

7,31

 

6,76

 

13,63

 

Average number of shares, 000'

 

16 618

 

8 285

 

16 618

 

8 285

 

10 576

 

8 493

 

Number of shares at closing of period, 000'

 

16 618

 

8 285

 

16 618

 

8 285

 

16 618

 

16 618

 

Share price at end of period, SEK

 

4,52

 

18,09

 

4,52

 

18,09

 

4,52

 

7,80

 

Number of sold electrodes, pieces

 

3 088

 

3 440

 

11 606

 

12 768

 

15 542

 

16 704

 

Average number of employees

 

19

 

21

 

19

 

22

 

20

 

21

 

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on November 13, 2018.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com. 

Contact person:
Michael Colérus, CFO

For more information, please contact: 
Simon Grant, CEO SciBase 
Phone: +46-72-887-43-99 
Email: simon.grant@scibase.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/scibase/r/interim-report,c2670207

The following files are available for download:

http://mb.cision.com/Main/12371/2670207/943454.pdf

PDF

 

Voltar noticias em Inglês